MX2024006550A - Composiciones farmaceuticas para el tratamiento del dolor visceral. - Google Patents
Composiciones farmaceuticas para el tratamiento del dolor visceral.Info
- Publication number
- MX2024006550A MX2024006550A MX2024006550A MX2024006550A MX2024006550A MX 2024006550 A MX2024006550 A MX 2024006550A MX 2024006550 A MX2024006550 A MX 2024006550A MX 2024006550 A MX2024006550 A MX 2024006550A MX 2024006550 A MX2024006550 A MX 2024006550A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- treatment
- visceral pain
- compositions
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000009935 visceral pain Diseases 0.000 title abstract 2
- 208000005615 Interstitial Cystitis Diseases 0.000 abstract 2
- 206010005063 Bladder pain Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229940096976 rectal foam Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona péptidos, composiciones farmacéuticas, composiciones farmacéuticas líquidas; composiciones farmacéuticas de espuma rectal; y métodos para fabricar y usar las mismas, que pueden usarse para el tratamiento de una condición de dolor visceral (por ejemplo, dolor de vejiga asociado con cistitis intersticial/síndrome de dolor de vejiga (IC/BPS).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163283731P | 2021-11-29 | 2021-11-29 | |
US202263382612P | 2022-11-07 | 2022-11-07 | |
PCT/US2022/080490 WO2023097309A1 (en) | 2021-11-29 | 2022-11-28 | Pharmaceutical compositions for the treatment of visceral pain |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2024006550A true MX2024006550A (es) | 2024-06-12 |
Family
ID=84689174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2024006550A MX2024006550A (es) | 2021-11-29 | 2022-11-28 | Composiciones farmaceuticas para el tratamiento del dolor visceral. |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4440595A1 (es) |
KR (1) | KR20240111797A (es) |
AU (1) | AU2022398687A1 (es) |
CA (1) | CA3238619A1 (es) |
IL (1) | IL313184A (es) |
MX (1) | MX2024006550A (es) |
WO (1) | WO2023097309A1 (es) |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2968628A (en) | 1958-10-17 | 1961-01-17 | Shulton Inc | Propellant composition |
US3966090A (en) | 1969-02-17 | 1976-06-29 | Dart Industries Inc. | Package for dispensing an antiseptic composition |
US3714140A (en) | 1971-03-16 | 1973-01-30 | Squibb & Sons Inc | Peptide synthesis |
US3970219A (en) | 1975-03-03 | 1976-07-20 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols and process |
US4411994A (en) | 1978-06-08 | 1983-10-25 | The President And Fellows Of Harvard College | Protein synthesis |
US4440320A (en) | 1981-11-30 | 1984-04-03 | Wernicke Steven A | Foam dispensing apparatus |
AU5963290A (en) | 1989-06-30 | 1991-01-17 | Massachusetts Institute Of Technology | Inhibition of the n-end rule pathway in living cells |
US5443369A (en) | 1993-06-09 | 1995-08-22 | Ingersoll-Rand Company | Self-contained instrument and seal air system for a centrifugal compressor |
NL1001366C2 (nl) | 1995-10-06 | 1997-04-08 | Airspray Int Bv | Inrichting voor het afgeven van een luchtvloeistofmengsel, in het bijzonder schuim en daarvoor bestemde bedieningseenheid. |
US6547162B1 (en) | 1998-04-17 | 2003-04-15 | Keltub B.V. | Foam spraying device |
US7504253B2 (en) | 1999-06-11 | 2009-03-17 | The Burnham Institute For Medical Research | Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof |
US7785832B2 (en) | 2000-05-09 | 2010-08-31 | HALLA Patent & Law Firm | Method of protein synthesis |
NL1016694C2 (nl) | 2000-11-23 | 2002-05-24 | Keltub B V | Schuimvormingseenheid. |
US6875438B2 (en) | 2002-04-27 | 2005-04-05 | Aventis Pharma Deutschland Gmbh | Preparations for topical administration of substances having antiandrogenic activity |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
NL1022456C2 (nl) | 2003-01-21 | 2004-07-22 | Packaging Tech Holding Sa | Drukverpakkingssysteem voor het op een in een drukverpakking opgenomen fluïdum aanbrengen van een werkdruk. |
NL1022633C2 (nl) | 2003-02-10 | 2004-08-12 | Keltub B V | Verbeterde schuimvormingseenheid. |
NL1024350C2 (nl) | 2003-09-23 | 2005-03-24 | R & D Injector Ag | Afgifte-eenheid voor geconcentreerd injecteren. |
NL1028921C2 (nl) | 2005-04-29 | 2006-11-01 | Airspray Nv | Afgifte-inrichting. |
US7735692B2 (en) | 2006-10-10 | 2010-06-15 | Meadwestvaco Calmar, Inc. | Rotating dispenser head with locking and venting closure connector for an air foaming pump dispenser |
WO2008147536A1 (en) | 2007-05-24 | 2008-12-04 | President And Fellows For Harvard College | Methods and compositions for enhancing proteasome activity |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
CN102686205A (zh) | 2009-10-02 | 2012-09-19 | 弗艾米克斯有限公司 | 局部四环素组合物 |
US20120028286A1 (en) | 2010-07-30 | 2012-02-02 | Saller Charles F | Method for evaluating the breakdown of proteins, polypeptides and peptides |
US9429566B2 (en) | 2011-09-28 | 2016-08-30 | Université de Montréal | Assay for inhibitors of CIP/KIP protein degradation |
EP3288578B8 (en) * | 2015-05-01 | 2023-03-29 | Ironwood Pharmaceuticals, Inc. | Compositions for colon cleansing and the treatment of gastrointestinal disorders |
GB2554365B (en) | 2016-09-22 | 2022-05-04 | Aer Beatha Ltd | Canister and valve |
JP2020512292A (ja) * | 2016-12-21 | 2020-04-23 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 |
-
2022
- 2022-11-28 IL IL313184A patent/IL313184A/en unknown
- 2022-11-28 CA CA3238619A patent/CA3238619A1/en active Pending
- 2022-11-28 MX MX2024006550A patent/MX2024006550A/es unknown
- 2022-11-28 AU AU2022398687A patent/AU2022398687A1/en active Pending
- 2022-11-28 KR KR1020247021287A patent/KR20240111797A/ko unknown
- 2022-11-28 EP EP22834821.5A patent/EP4440595A1/en active Pending
- 2022-11-28 WO PCT/US2022/080490 patent/WO2023097309A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2023097309A1 (en) | 2023-06-01 |
IL313184A (en) | 2024-07-01 |
CA3238619A1 (en) | 2023-06-01 |
EP4440595A1 (en) | 2024-10-09 |
KR20240111797A (ko) | 2024-07-17 |
AU2022398687A1 (en) | 2024-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
MX2024000348A (es) | Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. | |
EA201891946A1 (ru) | Коагонисты глюкагона и glp-1 для лечения ожирения | |
MX2018013150A (es) | Composición de hidrogel médico, e hidrogel médico, método de preparación del mismo y aplicación del mismo. | |
MX2019012464A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. | |
PH12020551144A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX2015015249A (es) | Peptidos terapeuticos. | |
MX2021003187A (es) | Inhibición de la peptidasa específica de ubiquitina 9x. | |
MX2020007876A (es) | Terapia genica para la distrofia muscular de cinturas tipo 2c. | |
MX2024006288A (es) | Dispositivos de suministro de farmacos in vivo y metodos para el suministro de farmacos. | |
MX2020004666A (es) | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. | |
MX2021007453A (es) | Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo. | |
SG10201803112RA (en) | Liquid treatment apparatus | |
MX2018001720A (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos. | |
PH12017501290A1 (en) | Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide | |
MX2019013096A (es) | Peptidos para el tratamiento de diabetes. | |
ZA202211980B (en) | Methods and treatment of trauma | |
MX2018016003A (es) | Tratamiento combinado para lesiones neurológicas. | |
PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
MX2020004058A (es) | Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos. | |
MX2024006550A (es) | Composiciones farmaceuticas para el tratamiento del dolor visceral. | |
PH12021551138A1 (en) | Application of chidamide in combination with r-chop, and drug combination | |
MX2019014867A (es) | Metodo para tratar un efecto secundario de la inmunoterapia. | |
MX2022005376A (es) | Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas. |